SEC Form 4 · accession 0001567619-18-000239
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian Mueller
Officer — SVP, Corporate Controller
Period of report
Aug 7, 2018
Accepted (ET)
Aug 9, 2018 · 4:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 7, 2018 | M | 1,718 | $28.23 | A | 14,093 | D | |
| Common StockF1 | Aug 7, 2018 | M | 782 | $28.23 | A | 14,875 | D | |
| Common StockF1 | Aug 7, 2018 | S | 2,500 | $104.50 | D | 12,375 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F1,F2 | $28.23 | Aug 7, 2018 | M | 1,718 | D | Dec 1, 2011 | May 30, 2021 | Common Stock | 1,718 | 0 | D |
| Stock Option (Right to buy Common Stock)F1,F2 | $28.23 | Aug 7, 2018 | M | 782 | D | Dec 1, 2011 | May 30, 2021 | Common Stock | 782 | 6,709 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on March 9, 2018.
- F2Reflects the number of options outstanding after the transactions from this specific stock option grant.